Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Exclusion Criteria

• •Difficulty distinguishing migraine headache from tension-type other headaches
• •Has taken medication for acute treatment of headache (including acetaminophen, nonsteroidal anti-inflammatory drugs \[NSAIDs\], triptans, ergotamine, opioids, or combination analgesics) on 10 or more days per month in the previous 3 months
• •Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine
• •Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy
• •Required hospital treatment of a migraine attack 3 or more times in the previous 6 months
• •Has a chronic non-headache pain condition requiring daily pain medication
• •Has a history of malignancy in the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
• •Has a history of any prior gastrointestinal conditions (eg, diarrhoea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of investigational product; participants with prior gastric bariatric interventions which have been reversed are not excluded
• •Has a history of hepatitis within previous 6 months.